Cometriq (Cabozantinib-S-Malate): Uses, Side Effects & Warnings
Cometriq (Cabozantinib-S-Malate) is a prescription oral medication approved for the treatment of certain cancers, functioning as a targeted kinase inhibitor that disrupts tumor growth and spread. Understanding its approved uses, potential side effects, and critical safety warnings helps patients and caregivers make informed treatment decisions.
Key Takeaways
- Cometriq is FDA-approved for progressive, metastatic medullary thyroid cancer (MTC).
- It works by blocking multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.
- Common side effects include diarrhea, fatigue, nausea, and hand-foot syndrome.
- Serious risks include perforations, fistulas, severe hemorrhage, and thromboembolic events.
- Patients must disclose all medications to their provider due to significant drug interaction risks.
What Is Cometriq (Cabozantinib-S-Malate) Used for in Cancer Treatment
Cabozantinib-S-malate is the active salt form of cabozantinib, a multi-targeted receptor tyrosine kinase (RTK) inhibitor. The FDA approved Cometriq specifically for adults with progressive, metastatic medullary thyroid cancer (MTC). MTC is a relatively rare malignancy arising from parafollicular C cells of the thyroid, accounting for approximately 3–4% of all thyroid cancers according to the American Cancer Society. Because MTC can be resistant to conventional chemotherapy, targeted agents like Cometriq represent a meaningful therapeutic advance.
The drug exerts its anticancer effect by inhibiting several kinases simultaneously, including RET, MET, and VEGFR-1, -2, and -3. By blocking these pathways, it reduces tumor cell proliferation, limits angiogenesis (the formation of new blood vessels that feed tumors), and impairs metastatic spread. In the pivotal EXAM clinical trial, cabozantinib-S-malate demonstrated a statistically significant improvement in progression-free survival compared to placebo in patients with progressive MTC, supporting its regulatory approval.
Cometriq (Cabozantinib-S-Malate) Side Effects and Drug Interactions
Like all targeted oncology therapies, Cometriq cabozantinib uses and side effects must be carefully weighed against potential benefits. The most frequently reported adverse reactions include diarrhea, stomatitis, hand-foot skin reaction (palmar-plantar erythrodysesthesia), weight loss, decreased appetite, nausea, and fatigue. These effects can significantly impact quality of life and may require dose modification or supportive care management.
| Side Effect Category | Examples | Management Approach |
|---|---|---|
| Gastrointestinal | Diarrhea, nausea, stomatitis | Antidiarrheal agents, hydration, dietary adjustments |
| Dermatological | Hand-foot syndrome, rash | Topical emollients, dose reduction if severe |
| Metabolic | Weight loss, hypocalcemia | Nutritional support, electrolyte monitoring |
| Cardiovascular | Hypertension | Antihypertensive therapy, regular blood pressure monitoring |
Regarding Cometriq side effects and drug interactions, clinicians must exercise particular caution. Strong CYP3A4 inhibitors (such as ketoconazole or clarithromycin) can increase cabozantinib plasma concentrations, raising toxicity risk, while strong CYP3A4 inducers (such as rifampin or St. John’s Wort) may reduce drug efficacy. Patients should provide a complete medication list—including herbal supplements—to their oncology team before initiating therapy.
Cabozantinib-S-Malate Warnings, Contraindications, and Safety Information
Cabozantinib-S-malate warnings and safety information are extensive and require thorough patient counseling prior to treatment. The FDA label carries serious warnings for gastrointestinal perforations and fistula formation, which, although uncommon, can be life-threatening. Patients who develop severe abdominal pain should seek immediate medical evaluation.
Additional black-box level concerns include severe or fatal hemorrhage, thrombotic events such as pulmonary embolism or myocardial infarction, and hypertensive crisis. Wound healing complications are also documented; the drug should be withheld for at least 28 days before elective surgery and restarted only after adequate healing. Cometriq is contraindicated in pregnancy due to demonstrated fetal harm in animal studies, and both male and female patients of reproductive potential must use effective contraception during therapy and for a defined period after the final dose.
Key safety monitoring requirements include:
- Regular blood pressure checks throughout the treatment course
- Periodic laboratory assessment of hepatic function, thyroid-stimulating hormone (TSH), and electrolyte levels
- Urine protein testing to detect early signs of proteinuria
Dose reductions or permanent discontinuation may be necessary depending on the severity of adverse events. All decisions regarding starting, adjusting, or stopping Cometriq therapy should be made exclusively by a qualified oncology specialist based on the patient’s clinical profile and current prescribing guidelines.
